Deep CNS Disease Focus: Taysha specializes in developing gene therapies for severe monogenic central nervous system (CNS) disorders, an area of high unmet medical need with limited treatment options, allowing for focused expertise and potentially accelerated regulatory pathways.

Robust AAV Gene Therapy Platform: The company leverages a sophisticated adeno-associated virus (AAV) gene therapy platform, optimized for efficient and targeted delivery of therapeutic genes to the CNS, which is critical for treating neurological conditions.

Broad and Diversified Pipeline: Taysha boasts a pipeline with multiple gene therapy candidates across various rare and severe neurological diseases, diversifying development risks and increasing the probability of bringing multiple successful treatments to market.